Phoremost LtdProtein DegradersPhoremost reports Series B extensionBritish protein degrader specialist PhoreMost Ltd has extended its €33m Series B financing to $50M and plans to advance its oncology and inflammation degrader programmes. more ➔
FinancingFunding for green insecticidesAgri-biotech SOLASTA Bio Ltd. has raised US$14m in a Series A funding round led by Forbion. With the money, the UK company will advance its first-of-a kind peptide-based bioinsecticide. more ➔
AstraZenecaPhase IIIAZ’s lung cancer drug disappointsA Phase III trial evaluating AstraZeneca and Daiichi Sankyo’s potential “blockbuster” lung cancer drug Dato-DXd showed no significant improvement over standard chemotherapy. Investors reacted quickly: … more ➔
King's CollegeAllergyEpsilogen Ltd completes £12.5m Series B e...A new £12.5m Series B expansion brings Elipsogen Ltd’s total Series B funds raised to £43.25 million. The IgE antibody specialist will use the roceeds to support the delivery of clinical Proof of Concept … more ➔
Hayo Therapeutics SAObesitySwiss RNA maker Haya in huge licence dealSwiss HAYA Therapeutics SA has inked a US$1bn biobuck deal with pharma giant Eli Lilly to discover new lncRNA targets in obesity and related metabolic conditions. more ➔
Innerstream - wikimedia.orgMultiple sclerosisRoche with good interim clinical resultsRoche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression after one year in patients with relapsing multiple sclerosis more ➔
Individor plcPartnershipIndividor set to waive AEF0117 licence aft...Following the failure of Aelis Farma’s lead candidate AEF0117 in a Phase IIb study in patients with cannabis use disorder or cannabis-induced psychosis, Individor plc has stated that it will not exercise … more ➔
Nxtera Pharma LtdDealNxera Pharma Ltd collects clinical US$35m...Nxera Pharma Ltd has got a Phase II milestone from US licencor Neurocrine Biosciences for its first-in class oral schizophrenia candidate NBI-1117568. more ➔
marquetand - pixapay.comDrug developmentResearchers present AI-guided protein desi...Danish AI expert Francesco Pesce and collegues have expanded the toolbox for computational protein design. Their new algorithm will facilitate the design of proteins whose functions exploit the many … more ➔
Amiferia ABVetmedAmferia partners with Biokema expanding in...Swedish antimicrobial specialist Amferia AB has inked a contract is with the Swiss animal health company Biokema SA for commercialisation of Amferia’s proprietary antimicrobial wound care technology … more ➔
Phoremost Ltd
AstraZeneca
King's College
Hayo Therapeutics SA
Innerstream - wikimedia.org
Individor plc
Nxtera Pharma Ltd
marquetand - pixapay.com
Amiferia AB